Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to “Sell” at StockNews.com
StockNews.com lowered shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) from a hold rating to a sell rating in a research note published on Tuesday morning. Several other research analysts have also weighed in on the stock. Robert W. Baird lowered their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set […]
